Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management - 12/08/11

Abstract |
More than 20 North American academic centers account for the majority of hematopoietic stem cell transplantation (HCT) procedures for primary immunodeficiency diseases (PIDs), with smaller numbers performed at additional sites. Given the importance of a timely diagnosis of these rare diseases and the diversity of practice sites, there is a need for guidance as to best practices in management of patients with PIDs before, during, and in follow-up for definitive treatment. In this conference report of immune deficiency experts and HCT physicians who care for patients with PIDs, we present expert guidance for (1) PID diagnoses that are indications for HCT, including severe combined immunodeficiency disease (SCID), combined immunodeficiency disease, and other non-SCID diseases; (2) the critical importance of a high degree of suspicion of the primary care physician and timeliness of diagnosis for PIDs; (3) the need for rapid referral to an immune deficiency expert, center with experience in HCT, or both for patients with PIDs; (4) medical management of a child with suspicion of SCID/combined immunodeficiency disease while confirming the diagnosis, including infectious disease management and workup; (5) the posttransplantation follow-up visit schedule; (6) antimicrobial prophylaxis after transplantation, including gamma globulin administration; and (7) important indications for return to the transplantation center after discharge. Finally, we discuss the role of high-quality databases in treatment of PIDs and HCT as an element of the infrastructure that will be needed for productive multicenter clinical trials in these rare diseases.
Le texte complet de cet article est disponible en PDF.Key words : Allogeneic hematopoietic stem cell transplantation, gene therapy, primary immunodeficiency, clinical trial
Abbreviations used : ADA, ALC, CGD, CIBMTR, CID, CMV, CT, Cy, GT, GVHD, HCT, HLH, NK, PCP, PE, PID, PIDTC, SCID, TMP/SMX, USIDNET, WAS
Plan
| This workshop was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, and the Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md. |
|
| Disclosure of potential conflict of interest: M. J. Cowan has received research support from the National Institutes of Health; has provided expert witness testimony on the topic of transplant-related mortality; and is Chair of PSIG at the American Society for Blood and Marrow Transplantation. L. D. Notarangelo has received research support from the Manton Foundation, and is on the Steering Committee for the United States Immunodeficiency Network. J. Puck has received research support from the National Institutes of Health, Jeffrey Modell Foundation, United States Immunodeficiency Network, and Baxter, Inc. R. H. Buckley has received research support from the National Institutes of Health, and is Chair of the Medical Advisory Committee for the Immune Deficiency Foundation. M. E. Conley is a consultant for Pharmacyclics; has received royalties from Santa Cruz Biotechnology; and has received research support from the National Institutes of Health. H. R. Gaspar has received research support from the Medical Research Council (UK) and the European Union. H. D. Ochs is on advisory boards for Baxter and CSL Behring, and has received research support from the Jeffrey Modell Foundation, Genetic Defects of Immunity (NIH/NIAID), and Flebogamma 5%. T. N. Small is speaker for Pfizer; is on an advisory board for Wyeth; is on the Data and Safety Monitoring Committee for the American Medical Directors Association; and is married to an employee of Pfizer. The other authors declare that they have no relevant conflicts of interest to disclose. |
|
| The opinions expressed are those of the authors and do not represent the position of the National Institute of Allergy and Infectious Diseases, the Office of Rare Diseases Research, the National Institutes of Health, or the US Government. |
|
| Report of a workshop sponsored by the National Institute of Allergy and Infectious Diseases and the Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md, May 21-22, 2009. |
Vol 124 - N° 6
P. 1152 - décembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
